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Abstract
Background: There are major challenges in ensuring medication safety and preventing adverse drug events in older
people. Older people are especially vulnerable to drug-to-drug interactions (DDIs). However, when older patients are
transferred from hospital to home care, information related to DDIs is limited. The objectives of this study were to (1)
identify and describe potential DDIs in older patients discharged from hospital to home care and (2) identify patient
and hospital transfer characteristics associated with the potential DDIs.
Methods: This is a cross-sectional study of patients discharged from medical hospital wards to home care in
central Norway. Nursing transfer documents, including medication lists, were reviewed from records of 99
older inpatients on the day of discharge. The patients’ drug regimens were screened using the Norwegian
drug interaction database, www.interaksjoner.no. Descriptive statistics and univariable and multivariable linear
regression analyses were used to analyze the data.
Results: The mean age of the sample was 82.9 years; 58.6% were female. In total, 274 DDIs were identified.
Major DDIs were identified in two patients, moderate DDIs in 80 patients, and minor DDIs in 40 patients. At
least one potential DDI was found for 84 of the patients, with an average of 2.77 DDIs per patient. The most
frequent DDIs were related to the concomitant use of alendronate and calcium. Warfarin treatments were
frequently linked to DDIs. Potential DDIs were associated with the number of prescribed drugs, age, and
living situation.
Conclusions: This study shows that potentially clinically relevant DDIs are common for older patients transferred from
hospital to home care and pose a risk for these patients’ health. Monitoring for potential DDIs is highly important to
ensure patient safety, and home care nurses might play a significant role through awareness and early recognition.
Keywords: Drug-to-drug interactions, Older patients, Patient safety, Hospital discharge, Primary care, Norway
Background
Drugs are essential in the care and treatment of older
patients, and used correctly, drugs contribute to better
health and increased quality of life for many. However,
there are major challenges in ensuring medication safety
and preventing adverse drug events (ADEs) in older
people [1–3]. A specific type of ADE, a drug-to-drug
interaction (DDI), occurs when one drug changes the
effect of another drug. Older people are especially vul-
nerable to DDIs and DDI-related adverse events because
of age-related pharmacodynamic and pharmacokinetic
changes, an increased risk for multimorbidity and,
consequently, polypharmacy [4]. DDIs contribute to ad-
verse drug reactions (ADR) and the burden of iatrogenic
illnesses in older people [5]. They also increase hospital
visits and admissions [6], hospital readmission [7], and
mortality [8] and represent a significant burden in terms
of healthcare costs [9].
For older people, discharge from hospital to home is an
especially vulnerable situation. They often have complex
care needs caused by multimorbidity and multiple func-
tional limitations [10, 11]. In addition, the overlap of acute
and chronic diseases when transferred from hospital may
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increase older patients’ susceptibility to ADRs [5], including
ADRs caused by DDIs. During hospitalization, extensive
changes may be made in the patients’ medication regimen
[12], with prescription of new drugs causing new potential
DDIs. After discharge, the patients most often face a drastic
decrease in the number of supporting personnel to assist
them in successfully complying with an often new and
more complex drug regimen [13]. The patient might be
without helping relatives and with sparse follow-up care
from home health nursing; thus, the self-management skills
of the patient are essential. The general practitioner (GP)
must decide whether or not to maintain the change in the
patient’s medication regimen; however, incomplete commu-
nication about medication management between the hos-
pital and GP at the time of discharge is common [12, 14].
In addition, discrepancies may occur between the hospital
discharge medication list and the list of medications that
the patient actually uses at home [15, 16].
Although numerous studies have evaluated potentially
inappropriate medication use among older people, infor-
mation related to DDIs in older patients transferred
from hospital to home care is limited. The objectives of
this study were to (1) identify and describe potential
DDIs in older patients discharged from hospital to home
care and (2) identify patient and hospital transfer charac-
teristics associated with the potential DDIs.
Methods
Study setting and sample
A cross-sectional study using consecutive sampling was
carried out at a general medicine ward and a geriatric
unit at a local hospital in central Norway from August
2010 to June 2011. The sample consisted of nursing
transfer documents and medication lists from records of
older inpatients admitted from their own homes. The
criteria for inclusion were that the patients were 70+
years of age and consent competent and that they re-
ceived home health nursing both before and after the
hospitalization. Contact persons at the hospital wards
evaluated all patients for the inclusion criteria and en-
rolled the participants. A sample size of 100 was deter-
mined appropriate [17, 18]. Recruitment was challenging
because many of the patients did not fulfill the criteria
for receiving home health nursing after hospitalization:
due to bad condition, they were discharged to a higher
care level in primary care (i.e., nursing home). Overall,
111 patients met the inclusion criteria. Of these, nine re-
fused to participate and three were excluded due to lack
of information regarding medical prescriptions, leaving
99 patients enrolled in the study.
Data collection
Hospital transfer documents and background data were
retrieved (by the contact persons) from the patient records
on the day of discharge. Information on prescription drugs
(drug names, dosage, and frequency) was collected from
the physicians’ discharge notes. These were attached to
the nursing discharge notes because they contained medi-
cation information, intended for medication administra-
tion by home health nurses. Background data were used
to identify patient characteristics (age, gender, living situ-
ation, housing situation, and distance from hospital) and
hospital transfer characteristics (type of hospitalization, re-
admission status, medical department facility, and length
of hospital stay).
Drug use and potential drug-to-drug interactions
All drugs were classified according to the Anatomical
Therapeutic Chemical Classification (ATC) code. Vari-
ables of drug use included; prescribed drugs (in total),
scheduled drugs, and drugs “as required” (pro re nata).
The potential DDIs were identified and evaluated by
the interdisciplinary research team, i.e., a registered
nurse (first author) and a pharmacist (second author).
We used the database www.interaksjoner.no to check
for DDIs. The database is maintained by the Norwegian
Medicines Agency [19]. It contains information on
both pharmacodynamic and pharmacokinetic drug in-
teractions classified into three categories according to
the “traffic light system” in terms of clinical relevance,
i.e., assumed severity (major, moderate, minor). Red
alerts in the database concern drug combinations to
avoid (major), yellow alerts concern drugs that may be
combined, but precautions need to be taken, e.g., dose
changes or monitoring of clinical and/or laboratory pa-
rameters (moderate), and green alerts concern drugs
where there is only a theoretical chance of a DDI, and
drugs may be combined (minor). Some DDIs that ap-
pear in the database are clinically relevant only under
specific circumstances, e.g., an interaction between
warfarin and paracetamol, with a resulting increase in
the international normalized ratio (INR) is only rele-
vant if the doses of paracetamol are high, and treat-
ment continues for several days. This was taken into
account in our evaluation of the potential DDIs. How-
ever, it was not possible to assess whether all such cir-
cumstances were fulfilled, due to uncertainty in this
information (e.g., paracetamol is often taken “as re-
quired”). The number of DDIs was classified on the
basis of the pharmaceutical preparations instead of the
pharmacological substances. Thus, the preparation Cal-
cigran Forte® for example, which contains calcium and
vitamin D, has only one DDI in combination with hy-
drochlorothiazide, although both calcium and vitamin
D increase the risk of hypercalcemia in combination
with hydrochlorothiazide. The database contains infor-
mation on DDIs for ATC group levels (e.g., A10 drugs
used in diabetes) that may not be clinically relevant for
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all specific drugs in this ATC group, and these DDIs
were not included in the results. For example, metfor-
min (A10BA02) and the ACE-inhibitor enalapril appar-
ently interact according to the database, resulting in an
increased hypoglycemic effect; however, metformin
does not increase the risk of hypoglycemia, and the
DDI is not clinically relevant in this case.
Statistical analysis
SPSS version 23.0 for Windows (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis. Descriptive statis-
tics were expressed as medians and ranges or means and
standard deviations (SD) for continuous variables (where
appropriate) and as frequencies and percentages for cat-
egorical variables. Univariable analyses were performed
to estimate the effect of covariates (patient and hospital
transfer characteristics—used as categorical variables
and number of prescribed drugs—used as a continuous
variable) on the occurrence of potential DDIs. Variables
showing a trend in association in univariable analysis (p
< 0.2) were included in the multivariable linear regres-
sion analysis (using the Enter method) to control con-
founding effects. Several models were tested, and
variables were removed until the remaining individual
variables had a p value < 0.1. Two-sided p values < 0.05
were considered significant. Modeling results are re-
ported as unstandardized and standardized regression
coefficients, p values, and 95% confidence intervals.
Results
Characteristics of the study population
The mean age of the study population (N = 99) was
82.9 years (SD = 6.1; range = 70 to 95 years). As shown in
Table 1, 58.6% were females. Most of the patients lived
alone (69.7%), in their own homes (71.7%), and within a
half hour driving time distance from the hospital (53.5%).
With regard to the medical department, 32.3% of the pa-
tients were admitted to the geriatric unit and 67.7% to the
general medicine ward. Most admissions were urgent
(83.8%) and 25.3% were readmissions (within 30 days after
discharge). The length of hospital stay varied between 1
and 24 days (mean = 7.12; SD = 4.5). The most common
causes of hospitalization were pneumonia (31.3%) and
chronic obstructive pulmonary disease (12.1%).
Drug use
The total number of drugs prescribed were 1108, includ-
ing 978 scheduled drugs and 130 drugs to be taken “as
required.” On average, the patients used 11.3 drugs (me-
dian = 11, SD = 3.5), with a range of 2 to 25 drugs. All
except one patient used five drugs or more. The number
of scheduled drugs per patient was on average 9.88 (SD
= 3.3; range = 2–21), and for “as required” drugs, the
average per patient was 1.30 (SD = 1.4; range = 0–6).
In total, the patients used 156 different drugs (i.e., ac-
tive substances). Of these, the most frequently pre-
scribed drugs were prednisolone and metoprolol, both
used by 51 of the patients (51.5%).
Potential drug-to-drug interactions
Among the 99 patients in the sample, we found at least
one potential DDI for 84 (84.8%) of the patients: major
DDIs were identified in two patients, moderate DDIs in
80 patients, and minor DDIs in 40 patients. In total, 274
DDIs were identified, with an average of 2.77 DDIs per
patient (median = 2.0; SD = 2.36). The maximum num-
ber of potential DDIs identified was 10 in a regimen
comprising 17 drugs. According to severity classification,
2 (0.7%) of the DDIs were major, 205 (74.8%) were mod-
erate, and 67 (24.5%) were minor.
Table 1 Characteristics of the sample, N = 99
Characteristics n (%)
Patient characteristics
Gender
Male 41 (41.4)
Female 58 (58.6)
Age, years
70–84 54 (54.5)
85–95 45 (45.5)
Living situation
Living alone 69 (69.7)
Living with someone 30 (30.3)
Housing situation
Sheltered housing 28 (28.3)
Own home 71 (71.7)
Distance from the hospital
< ½ h 53 (53.5)
> ½ h 46 (46.5)
Hospital transfer characteristics
Type of hospitalization
Urgent 83 (83.8)
Elective 16 (16.2)
Readmission
Yes 25 (25.3)
No 74 (74.7)
Medical department facility
Geriatric 32 (32.3)
Non-geriatric 67 (67.7)
Hospital length of stay in days
1–6 52 (52.5)
7–29 47 (47.5)
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Antibiotic agents were involved in 38 DDIs, including
the two drug combinations causing potential DDIs clas-
sified as major (identified in two different medication re-
gimes): ciprofloxacin (ATC J01M A02) and melatonin
(ATC N05C H01), and erythromycin (ATC J01F A01)
and simvastatin (ATC C10A A01). In addition, amoxicil-
lin, mycostatin, pivmecillinam, metronidazole, and phe-
noxymethylpenicillin were identified in potential DDIs.
Table 2 shows the most common potentially clinically
relevant (moderate severity) DDIs identified, and a de-
scription of the mechanism, and possible precautions,
for handling of the DDIs. These DDIs involved regu-
larly used drugs, e.g., alendronate, calcium, warfarin,
and paracetamol. Six drug combinations accounted for
37% of the moderate DDIs. Warfarin was frequently in-
volved in potential DDIs, accounting for 24% (N = 66)
of all the DDIs. In total, 80 dissimilar drug interaction
pairs were identified.
Factors associated with potential DDIs
Results from both univariable linear regression and the
multivariable linear regression analyses assessing the rela-
tionship between DDIs and independent variables are
given in Table 3. Univariable analysis showed a statistically
significant correlation between the number of potential
DDIs and living situation (p value < 0.001), number of pre-
scribed drugs (p value < 0.001), age (p value = 0.008), and
housing situation (p value = 0.033). There was no signifi-
cant relationship with gender, distance from hospital, type
of hospitalization, length of hospital stay, readmission sta-
tus, or hospital facility.
Multivariable linear regression analyses showed that
age, number of prescribed drugs, and living situation
were significantly associated with DDIs, after controlling
for the housing situation. These variables accounted for
approximately 47% of the variability in DDIs (p value <
0.001) (Table 3). Age has a negative influence on DDIs,
i.e., patients of a younger age are more likely to experi-
ence DDIs. Patients living with someone are also more
likely to have DDIs than patients living alone. For every
one-unit increase in the number of drugs, the number of
DDIs increases by on average 0.33.
Discussion
The objectives of this study were to identify and describe
potential DDIs in older patients discharged from hospital
Table 2 The most common potential clinically relevant drug-to-drug interactions (DDIs) in 99 older patients discharged from hospital to
home care
Drug-to-drug interaction
(ATC code)
Example of
drug combinations
Number
of patients
Mechanism of interaction Potential precautions or handling of the drug-
to-drug interaction
Alendronate (M05B
A04)–calcium
carbonate/vitamin D3 in
combination (A12A X-)
Fosamax®–
Calcigran Forte®
16 When taken simultaneously per os,
calcium-containing drugs may decrease
the absorption of peroral bisphosphonates.
Bisphosphonates should be taken at least 1
h before or 2 h after the calcium-containing
drugs. For drugs containing more than
1000 mg of calcium, bisphosphonates should
be taken at least 3 h before calcium.
Warfarin (B01A A03)–
paracetamol (N02B E01)
Marevan®–Paracet® 14 Paracetamol may reduce the
concentration of some coagulation factors
and increase the effect of warfarin, with an
increase in INR. The use of 1 g
paracetamol 4 times per day for 3–4 days
consecutively increased INR with a mean
of 0.5 units.
Monitor INR during concomitant use. The
use of paracetamol in combination with
warfarin is far safer than using for example.
NSAIDs when analgesics are required.
Digitalis glycosides
(C01A)–high-ceiling
diuretics (C03C)a
Digitoxin®–Furix® 12 Loop-diuretics may result in hypokalemia
and consequently lead to an increased
toxicity of digitoxin, although its blood
concentrations remain unchanged.
Monitor blood potassium concentration.
Warfarin (B01A A03)–
prednisolone (H02A B06)
Marevan®–
Prednisolon®
12 Unclear mechanism. INR may increase
when combining warfarin with high-dose
glucocorticoids.
Monitor INR and adjust warfarin dosage.
Benzodiazepine-related
drugs (N05C F)–opioids
(N02A)a
Zopiclone®–
OxyNorm®
11 Increased sedative effects. Sporadic
combination of the drugs is acceptable.
Clinical monitoring for sedative effects.
Special consideration of this drug
combination is required in frail, elderly
patients with non-malign pain.
Warfarin (B01A A03)–
allopurinol (M04A A01)
Marevan®–Zyloric® 10 Unclear mechanism. Allopurinol may
inhibit the metabolism of warfarin in some
individuals and thereby increase the effect
of warfarin, and INR.
Monitor INR and adjust warfarin dosage.
All DDIs were classified as moderate (drugs may be combined but precautions must be taken) according to the Norwegian database www.interaksjoner.no. The
description of mechanism and possible precautions and handling is also based on this database
INR international normalized ratio, NSAIDs non-steroidal anti-inflammatory drugs
aThese interactions are described on a higher level of ATC codes involving several active substances
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to home care and to identify patient and hospital transfer
characteristics associated with potential DDIs. Potential
DDIs, particularly moderate ones, were common in this
population (84.8%). This is in agreement with Marusic
et al. [20] who found potential DDIs in 85.6% (190 out of
222) of older patients discharged from an internal medi-
cine clinic in Croatia, but somewhat in contrast to Pasina
et al. [8] who reported potential DDIs in 60.5% (1642 out
of 2712) of an equivalent patient group in Italy. A major
limitation in our study is the lack of information on
whether or not the potential DDIs actually led to ADRs or
a change of therapeutic effect. Marusic et al. [20] followed
patients for 30 consecutive days after discharge and de-
tected actual DDIs in 21 (9.5%) of the patients, where two
lacked therapeutic effect and 19 experienced ADRs. Thus,
our results almost certainly overestimate the prevalence of
actual DDIs. Furthermore, the patients may not take all
drugs as prescribed, and prescribers may be well aware of
the DDIs, e.g., have adjusted the dosage or followed moni-
toring parameters.
The most common DDIs identified in this study
(Table 2) are in accordance with other studies. Warfarin
is well known for its DDI potential [20], as are digitalis
glycosides [9]. In addition, a high number of DDIs con-
cerning alendronate and calcium carbonate/vitamin D3
were detected in this sample, and these drugs are fre-
quently combined for the treatment of osteoporosis. In
order to avoid reduced absorption of alendronate, drugs
Table 3 Univariable and multivariable linear regression analysis for drug-to-drug interactions in older patients discharged from
hospital, N = 99
Variables Univariable Multivariable
Coefficient B 95% CI p value Standardized β Coefficient B 95% CI P value Standardized β
Gender
Male Ref
Female 0.020 − 0.941 to 0.980 0.968 0.004
Age, year
70–84 Ref Ref
85–95 − 1.244 − 2.161 to − 0.328 0.008 − 0.264 − 1.104 − 1.821 to − 0.387 0.003 − 0.234
Living situation
Living alone Ref Ref
Living with someone 2.390 1.480 to 3.300 < 0.001 0.468 1.236 0.377 to 2.095 0.005 0.242
Housing situation
Sheltered housing Ref Ref
Own home 1.120 0.094 to 2.146 0.033 0.215 0.129 − 0.693 to 0.951 0.756 0.025
Distance from the hospital
< ½ h Ref
> ½ h − 0.541 − 1.483 to 0.402 0.258 − 0.115
Type of hospitalization
Urgent Ref
Elective 0.650 − 0.629 to 1.928 0.316 0.102
Readmission
Yes Ref
No 0.438 − 0.647 to 1.524 0.425 0.081
Medical department facility
Geriatric Ref
Non-geriatric 0.442 − 0.566 to 1.449 0.386 0.088
Hospital length of stay
1–6 days Ref
7–29 days 0.564 − 0.377 to 1.504 0.237 0.120
Number of prescribed drugsa 0.405 0.295 to 0.515 < 0.001 0.595 0.331 0.219 to 0.443 < 0.001 0.487
CI confidence interval
aNumber of prescribed drugs was the only independent variable used as a continuous variable
Olsen and Sletvold Safety in Health  (2018) 4:8 Page 5 of 8
need to be taken at different time points during the day
[21]. Therefore, the prevention of this DDI is left to the
patient or the home health nurse administering the
drugs. This may be challenging, not least because the
patients at discharge often are in a vulnerable state, and
may have physical and cognitive impairment. Corbett
et al. [15] found that 40% of older patients had one or
more medication discrepancies at the patient level, e.g.,
intentional and non-intentional non-adherence and not
filling prescriptions, when transferred from hospital to
home. Consequently, the patient’s self-management
skills that are taught by the home health nurse are es-
sential. In the study of Sino et al. [22], 80.3% of the
home health nurses felt responsible for their older pa-
tients’ proper medication use, but the mean score for
knowledge of drug interactions was 77% of the max-
imum score.
Fortunately, the DDIs most frequently described in
our study may be preventable and/or manageable if the
prescribers have the complete overview of the patient’s
drug use. However, drugs taken “as required” may cause
special challenges in terms of DDIs, generating transient
DDIs that may be difficult to detect [4]. In this study,
the concomitant use of warfarin and paracetamol may
be worth noting (Table 2). Paracetamol in high doses
may increase the INR [19]. A meta-analysis of seven ran-
domized controlled trials (N = 225 patients) found that
paracetamol was associated with a mean 0.62 INR in-
crease (95% CI 0.46–0.78) compared to a placebo, when
the daily dosage of paracetamol was in the range of 1–
4 g [23]. Thus, the patients using warfarin that increased
their doses of paracetamol without informing the phys-
ician may be at increased risk of bleeding. Corbett et al.
[15] reported that older patients transferred from hospital
to home reported substituting prescribed pain medication
with pain medication they had at home. To substitute
paracetamol for non-steroidal anti-inflammatory drugs
(NSAIDs), resulting in a contraindicated DDI [19], may
have deleterious effects on the risk of bleeding. Moreover,
the warfarin interaction potential requires awareness, and
this study identified warfarin as responsible for a quarter
of the potential DDIs, including combination with the
corticosteroid prednisolone. A study of 32 patients on
long-term warfarin therapy that initiated short-term oral
corticosteroid therapy found a mean difference between
pre- and post-INR values of 1.24 (95% CI 0.86–1.62), and
16 patients (50%) required a modification of warfarin ther-
apy [24]. Thus, identification of warfarin drug combina-
tions to avoid, or ones that require precautions, is
essential to ensure the necessary monitoring and adjust-
ment of dosages.
As the patients in the present study were transferred
from hospital, the use of antibiotics in the study sample
was common and can be related to the frequent causes of
hospitalization, i.e., pneumonia and chronic obstructive
pulmonary disease. Therefore, we chose to focus on DDIs
involving prescribed antibiotic drugs. Antibiotic agents
were involved in 38 DDIs, of which two were contraindi-
cated. These DDIs may pose a particular challenge to pa-
tient safety, as the GP may neither be involved in patient
care nor get timely information from the hospital doctor
after discharge. Viktil et al. [12] found that only 24 out of
105 discharge notes of older patients discharged from gen-
eral medicine departments at Norwegian hospitals were
received within a week by the GPs. In the same study, they
found that extensive changes were made in drug regi-
mens, both during hospitalization and in the initial
months after discharge (3.4 versus 4.4 drug changes per
patient, respectively). Bakken et al. [25] studied patients
transferred from hospital to an intermediate-care nursing
home unit or hospital ward, and they found an increase in
the number of drugs from admission to discharge, mainly
due to treatment of infections and pain.
The finding of an association between DDIs and the
number of prescribed drugs is in accordance with several
other studies [e.g., 9, 26]. Age as a predictor of DDIs has
also been reported in previous research [e.g., 9]. How-
ever, in contrast to most other studies, we found that the
number of DDIs decreases with age: Patients aged 70–
84 years had significantly more DDIs than those aged 85–
95, even when controlling for other variables. Fialova et al.
[27], in a study of potentially inappropriate medication
(PIM) use in older patients (N = 2707) receiving home
care in eight European countries, found that PIM use was
negatively associated with age for patients of 85 years and
older. The authors suggest that this finding could be ex-
plained by greater physician awareness of PIM in the old-
est patients, or by a higher mortality rate in this age
group. Although Fialova et al. did not include DDIs in
their criteria for PIM, their explanation may also be trans-
ferrable to our findings.
Our result showing an association between DDIs and
living situation, i.e., those living with someone are more
likely to have DDIs, was somewhat surprising. A possible
explanation may be that patients living with someone re-
ceive help from their relatives and, consequently, receive
less follow-up care from the healthcare services. Unfor-
tunately, we do not have information about frequency of
assistance provided by the home health nursing services
in order to investigate this hypothesis.
Strengths and weaknesses
The small sample size, and the use of consecutive sam-
pling, limits the validity and generalizability of the results.
Although the patients in the sample were representative of
those in the hospital in terms of age and gender, a selection
bias may have occurred since we only enrolled patients
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with informed consent (and excluded those with cognitive
impairments, e.g., dementia).
This cross-sectional study used correlational analysis
in certain aspects, and therefore, only associations and
not causal relationships can be established. There is no
way to establish temporal sequences—that is, for ex-
ample, which came first the “DDIs” or the “Number of
prescribed drugs used.” According to R-squared, the
model explained 47% of the variance in DDI. This fact
suggests that other patient and transfer characteristics
were likely to be of importance.
The identification and assessment of potential DDIs
was performed by a registered nurse (first author) and a
pharmacist (second author), and this interdisciplinary
approach strengthens the analysis. We chose to use the
Norwegian drug interaction database [19], as this is a
well-known database in Norway, based on data from the
Norwegian Medicines Agency’s decision support system.
Both prescribers and pharmacists use this database. DDI
databases differ in the level of documentation and classi-
fication of DDIs [28], and our results may have been dif-
ferent if we had used other databases.
This study was concerned with potential DDIs based
on medication lists, and no attempt was made to deter-
mine whether the patients actually took the medications
or whether the interaction resulted in clinically relevant
DDIs. Studies have shown that errors in the medication
lists at the time of discharge from hospitals are common
[16]. Future research needs to assess the prevalence of
clinically relevant DDIs in older patients discharged
from hospital to home care.
Implications
Older patients discharged from hospital to home care are
frequently exposed to potential DDIs, and this requires
special awareness among healthcare professionals. In their
roles as caregivers and administrators of medications, with
regular contact with the patients, home care nurses are
particularly well positioned to be the most astute ob-
servers of DDIs and can recognize and monitor relevant
clinical symptoms. Thereby, nurse-led structured medica-
tion monitoring can be effective in preventing DDIs, as
previously described as an intervention to reduce adverse
drug reactions [29]. However, further studies are needed
to explore the potential benefits of such interventions. A
qualitative study from Sweden show that registered nurses
working in home care settings for older patients can con-
tribute in pharmacovigilance regarding these patients’
drug treatment [30]. Ensuring safe and effective drug
treatment for the individual patient should involve inter-
professional strategies. An interdisciplinary team including
GPs, nurses, and pharmacists can utilize the integrated
medicines management (IMM) model [31], which includes
medication reconciliation, medication review, and patient
education, with the aim of preventing and reducing DDIs
as well as other ADEs. Thereby, a multi-disciplined, profes-
sional team can contribute to medication safety for home-
dwelling older patients after hospital discharge.
Conclusions
The present study shows that potential DDIs are fre-
quent among older patients discharged from hospital to
home and that DDIs might be associated with the num-
ber of prescribed drugs, patient age, and living situation.
Monitoring for potential DDIs is highly important to en-
sure patient safety. In addition to the GP and pharma-
cist, home care nurses, who visit their patients in their
homes on a regular basis, can assist in early recognition
of potential DDIs in home-dwelling, older patients after
hospital discharge and thereby contribute to the safe use
of medicines.
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